Share this link via:
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Methodology
1.4 Assumptions & Limitations
1.5 Currency & Forecast Considerations
2.1 Market Snapshot
2.2 Key Findings
2.3 Analyst Perspective
2.4 Strategic Outlook
2.5 Opportunity Assessment
3.1 Introduction to Dual GLP-1/Amylin Therapies
3.2 Evolution of Incretin & Amylin-Based Metabolic Treatments
3.3 Mechanism of Action Overview
3.4 Therapeutic Positioning in Diabetes & Obesity Management
3.5 Value Chain Analysis
3.6 Clinical Development Landscape
3.7 Regulatory Framework Overview
3.8 Reimbursement & Access Landscape
3.9 Market Dynamics
4.1 Market Drivers
4.1.1 Rising Global Obesity & Type 2 Diabetes Burden
4.1.2 Superior Weight Loss & Glycemic Outcomes Versus Monotherapy
4.1.3 Expanding Cardiometabolic Risk Reduction Applications
4.1.4 Growing Demand for Non-Surgical Weight Management Solutions
4.2 Market Restraints
4.2.1 High Therapy Costs & Reimbursement Challenges
4.2.2 Manufacturing Complexity of Peptide-Based Combination Therapies
4.2.3 Limited Early Commercial Availability
4.3 Market Opportunities
4.3.1 Expansion into Type 1 Diabetes Adjunctive Therapy
4.3.2 Cardiovascular & Renal Outcome-Based Label Expansion
4.3.3 Oral Formulation Development
4.3.4 Emerging Market Penetration Opportunities
4.4 Market Challenges
4.4.1 Long-Term Patient Adherence Concerns
4.4.2 Regulatory & Clinical Trial Complexity
4.4.3 Competitive Pressure from Next-Generation Obesity Therapies
5.1 Clinical Pipeline Analysis
5.2 Mechanism & Combination Therapy Assessment
5.3 Patent & Intellectual Property Analysis
5.4 Manufacturing & Supply Chain Assessment
5.5 Regulatory & Approval Landscape
5.6 Pricing & Reimbursement Trends
5.7 Digital Health & Patient Monitoring Integration
5.7.1 Connected Injection Devices
5.7.2 Remote Metabolic Monitoring Platforms
5.7.3 AI-Based Treatment Personalization
5.7.4 Adherence & Patient Engagement Tools
5.8 Porter’s Five Forces Analysis
5.9 PESTLE Analysis
6.1 Fixed-Dose Combinations
6.2 Single Dual-Agonist Molecules
6.3 Co-Administered Regimens
7.1 Type 2 Diabetes Mellitus
7.2 Obesity & Weight Management
7.3 Cardiovascular Risk Reduction
7.4 MASH/NASH
8.1 Subcutaneous Injection
8.2 Oral Formulations
9.1 Hospitals & Specialty Clinics
9.2 Diabetes Care Centers
9.3 Ambulatory Care Settings
9.4 Home Healthcare
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 Germany
10.2.2 United Kingdom
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Rest of Asia Pacific
10.4 Middle East & Africa
10.4.1 UAE
10.4.2 Saudi Arabia
10.4.3 South Africa
10.4.4 Rest of Middle East & Africa
10.5 Latin America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Rest of Latin America
11.1 Market Share Analysis
11.2 Competitive Benchmarking
11.3 Pipeline & Product Positioning Analysis
11.4 Strategic Collaborations & Licensing Agreements
11.5 Mergers, Acquisitions & Partnerships
12.1 Novo Nordisk A/S
12.2 Eli Lilly and Company
12.3 AstraZeneca PLC
12.4 Zealand Pharma A/S
12.5 Boehringer Ingelheim GmbH
12.6 Sanofi S.A.
12.7 Amgen Inc.
12.8 Pfizer Inc.
12.9 Hanmi Pharmaceutical Co. Ltd.
12.10 Rhythm Pharmaceuticals Inc.
13.1 Future Market Outlook
13.2 Evolution of Combination Metabolic Therapies
13.3 Commercialization & Market Access Strategies
13.4 Strategic Recommendations for Manufacturers
13.5 Strategic Recommendations for Healthcare Providers & Investors
14.1 Abbreviations
14.2 Research Methodology Details
14.3 List of Tables & Figures
14.4 Disclaimer
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
27 May 2026
Intellectual Market Insights Research © 2026. All rights reserved.
